Out of diseases affecting kidney functions in humans, immunoglobulin A (IgA) nephropathy is the most common. Available treatments are mainly targeted to reduce proteinuria and creatinine levels and corticosteroids are the mainstay therapy to delay the end-stage renal disease (ESRD). However, corticosteroids are associated with dire adverse effects in 55% of the patients receiving the treatment consisting of metabolic disorders, osteoporosis, and others which drive the idea for the search for anti-inflammatory drugs which alleviate inflammation and fibrosis in the kidneys of the patients resulting in either cure or at least delay the ESRD. Phytomolecules have long been associated with the effective treatment of various disorders since ages. This study focuses on identifying the immunomodulatory pure molecules isolated from plants which can be studied for their effect in alleviating IgA nephropathy. All the phytomolecules mentioned in this study have inflammation-reducing properties as is evident from many studies mentioned here and IgA nephropathy, being an autoimmune disease, can be a good target of these phytomolecules. Various pathological pathways of IgA nephropathy can be targeted with these phytomolecules and this study is an effort to find out the rationale behind the choice of the molecules based on their ability to target the effector molecules of those pathological pathways.
Key words: Immunomodulator , Phytomolecules , End stage renal diseases, Immunoglobulin A nephropathy ,etc.
|